Theratechnologies Inc. (TH) - Total Liabilities
Based on the latest financial reports, Theratechnologies Inc. (TH) has total liabilities worth CA$79.19 Million CAD (≈ $57.29 Million USD) as of May 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TH operating cash flow to assess how effectively this company generates cash.
Theratechnologies Inc. - Total Liabilities Trend (1996–2024)
This chart illustrates how Theratechnologies Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Theratechnologies Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Theratechnologies Inc. Competitors by Total Liabilities
The table below lists competitors of Theratechnologies Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EQL PHARMA AB
F:7JK
|
Germany | €543.76 Million |
|
KB Star REIT Co. Ltd.
KO:432320
|
Korea | ₩846.86 Billion |
|
Formuepleje Limittellus
CO:FPILIM
|
Denmark | Dkr2.00K |
|
Silver X Mining Corp
V:AGX
|
Canada | CA$37.68 Million |
|
Cardiol Therapeutics Inc Class A
TO:CRDL
|
Canada | CA$5.74 Million |
|
SV Investment Corporation
KQ:289080
|
Korea | ₩24.78 Billion |
|
Sahamitr Pressure Container Public Company Limited
BK:SMPC
|
Thailand | ฿478.49 Million |
|
TGE Value Creative Solutions Corp
NYSE:BEBE
|
USA | $563.84K |
Liability Composition Analysis (1996–2024)
This chart breaks down Theratechnologies Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TH market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.01 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theratechnologies Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theratechnologies Inc. (1996–2024)
The table below shows the annual total liabilities of Theratechnologies Inc. from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-11-30 | CA$78.61 Million ≈ $56.87 Million |
-20.30% |
| 2023-11-30 | CA$98.64 Million ≈ $71.35 Million |
-14.84% |
| 2022-11-30 | CA$115.83 Million ≈ $83.79 Million |
+14.17% |
| 2021-11-30 | CA$101.45 Million ≈ $73.39 Million |
+4.68% |
| 2020-11-30 | CA$96.92 Million ≈ $70.11 Million |
+4.53% |
| 2019-11-30 | CA$92.72 Million ≈ $67.07 Million |
+21.68% |
| 2018-11-30 | CA$76.20 Million ≈ $55.12 Million |
+195.60% |
| 2017-11-30 | CA$25.78 Million ≈ $18.65 Million |
+32.78% |
| 2016-11-30 | CA$19.41 Million ≈ $14.04 Million |
-13.64% |
| 2015-11-30 | CA$22.48 Million ≈ $16.26 Million |
+3.89% |
| 2014-11-30 | CA$21.64 Million ≈ $15.65 Million |
+263.74% |
| 2013-11-30 | CA$5.95 Million ≈ $4.30 Million |
-56.74% |
| 2012-11-30 | CA$13.75 Million ≈ $9.95 Million |
-14.08% |
| 2011-11-30 | CA$16.01 Million ≈ $11.58 Million |
-14.08% |
| 2010-11-30 | CA$18.63 Million ≈ $13.48 Million |
-25.46% |
| 2009-11-30 | CA$25.00 Million ≈ $18.08 Million |
+331.28% |
| 2008-11-30 | CA$5.80 Million ≈ $4.19 Million |
-32.67% |
| 2007-11-30 | CA$8.61 Million ≈ $6.23 Million |
+51.34% |
| 2006-11-30 | CA$5.69 Million ≈ $4.11 Million |
+43.21% |
| 2005-11-30 | CA$3.97 Million ≈ $2.87 Million |
-5.60% |
| 2004-11-30 | CA$4.21 Million ≈ $3.04 Million |
-49.87% |
| 2003-11-30 | CA$8.39 Million ≈ $6.07 Million |
-18.27% |
| 2002-11-30 | CA$10.27 Million ≈ $7.43 Million |
-47.14% |
| 2001-11-30 | CA$19.43 Million ≈ $14.05 Million |
+18.05% |
| 2000-11-30 | CA$16.46 Million ≈ $11.91 Million |
+1001.62% |
| 1999-11-30 | CA$1.49 Million ≈ $1.08 Million |
-0.23% |
| 1998-11-30 | CA$1.50 Million ≈ $1.08 Million |
+1.47% |
| 1997-11-30 | CA$1.48 Million ≈ $1.07 Million |
-66.86% |
| 1996-11-30 | CA$4.45 Million ≈ $3.22 Million |
-- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more